Clinical Trial Update: Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating icotinib in plasma ctDNA EGFR mutation-positive non-small cell lung cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Plasma EGFR Mutation-positive Lung Cancer | Phase 2 | Status: UNKNOWN